Table 2.
The rate of ADRs estimated from post-market and RCT data. Numbers indicate the % of recipients suffer an ADR outcome; 95% confidence intervals are provided in parenthesis. For both infliximab ad adalimumab patients, the rate of ADR-associated death estimated from RCTs is not significantly different from zero
| ADR outcome | Infliximab (Remicade, Janssen Inc.) | Adalimumab (Humira, AbbVie Inc.) | ||
|---|---|---|---|---|
| Post-market | RCTs | Post-market | RCTs | |
| Death | 0.21% (0.09–0.33) | 0.01% (NS) | 0.18% (0.06–0.29) | 0.04% (NS) |
| Serious | 18.9% (15.8–22.1) | 13.1% (9.5–16.8) | 7.3% (4.8–9.7) | 16.3% (13.0–19.6) |
| All | 19.8% (16.8–22.8) | 74.9% (56.6–93.2) | 14.8% (10.2–19.5) | 48.7% (36.1–61.3) |
NS Not significant